牛牛AI助手已提取核心信息中慧生物2025年上半年收入达7112.3万元,较去年同期的697.8万元大幅增长919%,主要受益于四价流感病毒亚单位疫苗销售增长。期内毛利6078.1万元,毛利率达85.5%。研发投入9884.8万元,主要用于多款在研疫苗的临床试验及工艺开发。公司核心产品四价流感病毒亚单位疫苗已完成6-35月龄人群III期临床试验,并于2025年9月获国家药监局批准用于该年龄段人群。...
Source Link牛牛AI助手已提取核心信息中慧生物2025年上半年收入达7112.3万元,较去年同期的697.8万元大幅增长919%,主要受益于四价流感病毒亚单位疫苗销售增长。期内毛利6078.1万元,毛利率达85.5%。研发投入9884.8万元,主要用于多款在研疫苗的临床试验及工艺开发。公司核心产品四价流感病毒亚单位疫苗已完成6-35月龄人群III期临床试验,并于2025年9月获国家药监局批准用于该年龄段人群。...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.